Efficacy of Human Papillomavirus Vaccines
Authors:
- Lidia Rosi MedeirosLMLidia Rosi Medeiros
- Daniela Dornelles RosaDRDaniela Dornelles Rosa
- Maria Inês Da RosaMRMaria Inês Da Rosa
- Mary Clarisse BozzettiMBMary Clarisse Bozzetti
- Roselaine Ruviaro ZaniniRZRoselaine Ruviaro Zanini
- 1 October 2009
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 19 (7) , 1166-1176
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting InfectionJAMA, 2007
- Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialThe Lancet, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- CDC Panel Backs Routine HPV Vaccination2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000Perspectives on Sexual and Reproductive Health, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancersInternational Journal of Gynecology & Obstetrics, 2000